当前位置: X-MOL 学术J Cataract Refract Surg › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients.
Journal of Cataract & Refractive Surgery ( IF 2.6 ) Pub Date : 2019-10-01 , DOI: 10.1016/j.jcrs.2019.05.026
Ghasem Fakhraie 1 , Masoud Mirghorbani 2 , L Jay Katz 3 , Amirhossein Mollazadeh 2 , Zakieh Vahedian 2 , Reza Zarei 2 , Yadollah Eslami 2 , Masoud Mohammadi 2 , Nikoo Hamzeh 2 , Ahmad Masoomi 2
Affiliation  

PURPOSE To evaluate the effect of postoperative latanoprost administration on central macular thickness (CMT) after uneventful cataract surgery in glaucoma patients. SETTING Farabi Eye Hospital, Tehran, Iran. DESIGN Prospective randomized clinical trial. METHODS In this single-masked trial, glaucoma patients treated with latanoprost who had no other risk factor for the development of pseudophakic macular edema were randomly allocated to continuation of latanoprost or discontinuation of the drop after uneventful cataract surgery. At baseline and postoperatively at 1 month and 3 months, patients had complete ocular examinations and CMT measurements using optical coherence tomography. The main outcome measure was the change in the CMT between baseline measurements and postoperative measurements at 1 month and 3 months. RESULTS One hundred fifty-six eyes (latanoprost 76; discontinuation 80) finished the trial. There were no differences in baseline patient demographics or characteristics, including the CMT, between the two groups. There was transient increase in the mean CMT by 12 μm ± 49 (SD) in the latanoprost group at 1 month (P = .03); however, the value returned to baseline by 3 months (6 ± 55 μm; P = .27). The between-group difference in the mean change in the CMT from baseline was -3.1 μm (95% confidence interval [CI], -18.4 to 12.0; P = .68) after 1 month and -10.5 μm (95% CI, -26.6 to 5.5; P = .19) after 3 months; the differences were not significant. CONCLUSION Latanoprost administration after cataract surgery had no measurable effect on macular thickness.

中文翻译:

青光眼患者顺利进行白内障手术后,使用前列腺素类似物治疗类囊性黄斑水肿。

目的评估青光眼患者顺利进行白内障手术后拉坦前列素对中央黄斑厚度(CMT)的影响。地点伊朗德黑兰的法拉比眼科医院。设计前瞻性随机临床试验。方法在该单项掩盖试验中,接受拉坦前列素治疗且无其他危险因素导致假晶状体黄斑水肿的青光眼患者被随机分配至拉坦前列素继续治疗或白内障手​​术后停药。在基线以及术后1个月和3个月时,患者使用光学相干断层扫描进行了完整的眼部检查和CMT测量。主要结果指标是基线测量值和术后1个月和3个月测量值之间CMT的变化。结果156眼(拉坦前列素76;停药80)完成了试验。两组之间的基线患者人口统计学特征或特征(包括CMT)没有差异。拉坦前列素组在1个月时的平均CMT瞬时增加了12μm±49(SD)(P = .03);但是,该值在3个月后恢复到基线(6±55μm; P = 0.27)。1个月后,CMT与基线相比的平均组间差异为-3.1μm(95%置信区间[CI],-18.4至12.0; P = .68)和-10.5μm(95%CI,-) 3个月后为26.6至5.5; P = .19);差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。两组之间的基线患者人口统计学特征或特征(包括CMT)没有差异。拉坦前列素组在1个月时的平均CMT瞬时升高了12μm±49(SD)(P = .03);但是,该值在3个月后恢复到基线(6±55μm; P = 0.27)。1个月后,CMT与基线相比的平均组间差异为-3.1μm(95%置信区间[CI],-18.4至12.0; P = .68)和-10.5μm(95%CI,-) 3个月后; 26.6至5.5; P = .19);差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。两组之间的基线患者人口统计学特征或特征(包括CMT)没有差异。拉坦前列素组在1个月时的平均CMT瞬时升高了12μm±49(SD)(P = .03);但是,该值在3个月后恢复到基线(6±55μm; P = 0.27)。1个月后,CMT与基线相比的平均组间差异为-3.1μm(95%置信区间[CI],-18.4至12.0; P = .68)和-10.5μm(95%CI,-) 3个月后为26.6至5.5; P = .19);差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。拉坦前列素组在1个月时的平均CMT瞬时增加了12μm±49(SD)(P = .03);但是,该值在3个月后恢复到基线(6±55μm; P = 0.27)。1个月后,CMT与基线相比的平均组间差异为-3.1μm(95%置信区间[CI],-18.4至12.0; P = .68)和-10.5μm(95%CI,-) 3个月后为26.6至5.5; P = .19);差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。拉坦前列素组在1个月时的平均CMT瞬时增加了12μm±49(SD)(P = .03);但是,该值在3个月后恢复到基线(6±55μm; P = 0.27)。1个月后,CMT与基线相比的平均组间差异为-3.1μm(95%置信区间[CI],-18.4至12.0; P = .68)和-10.5μm(95%CI,-) 3个月后为26.6至5.5; P = .19);差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。差异不明显。结论白内障手术后给予拉坦前列素对黄斑厚度没有可测量的影响。
更新日期:2019-09-26
down
wechat
bug